Priv. Doz. Dr. Udo Hartwig (PhD) trained in Biomedicine from 1983 – 1988 at the Philipps-University Marburg and at the Charing Cross Sunley Research Centre in London, UK. As a scholar of the European Union he worked on immune responses and tolerance induction to viral (Mls) and microbial superantigens at the Laboratoire Genetique des Eucaryotes Moleculaire in Strasbourg (Dres. Mathis & Benoist), France and at the Ist. Dept. of Medicine, University Medical Center of Johannes Gutenberg-University Mainz (UMC) (Prof. Fleischer), and received his PhD in 1993. Following postdoctoral trainings at the Scripps Research Institute, Dept. of Immunology, in La Jolla, CA, USA (Dres S. Webb & J. Sprent) and the 3rd. Dept. of Medicine (Hematology & Medical Oncology) at the UMC, U. Hartwig started his own research group as a principal investigator at the 3rd. Dept. of Medicine, UMC, in 1998. His research interests focus on translational tumor immunology and cover multiple topics to improve adoptive cellular immunotherapy in acute myeloid leukemia and solid tumors embedded in a immunosuppressive tumor microenvironment including the development of novel therapeutics (e.g. TCR-like CARs, TCR-like bispecific antibodies). Moreover, U.Hartwig is Head of Production and Qualified Person in the Laboratory for Cellular Therapeutics at the 3rd. Dept. of Medicine which provides CD34+ hematopoietic stem cells, donor lymphocyte infusions and CAR engineered T cells for clinical applications.
